Stay updated on Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the efficacy or safety data related to the combination therapy of pembrolizumab plus axitinib versus sunitinib monotherapy for participants with advanced/metastatic renal cell carcinoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:17:42.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying health conditions and prior treatments required for inclusion in the study. Previously, this section had no information provided.
    Difference
    46%
    Check dated 2024-05-22T20:59:05.000Z thumbnail image
  8. Check
    42 days ago
    Change Detected
    Difference
    1.0%
    Check dated 2024-04-30T22:34:54.000Z thumbnail image

Stay in the know with updates to Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial page.